Skip to content
Viread(tenofovir disoproxil)
Atripla, Cimduo, Complera, Delstrigo, Eviplera, Stribild, Symfi, Truvada, Viread (tenofovir disoproxil) is a small molecule pharmaceutical. Tenofovir disoproxil was first approved as Viread on 2001-10-26. It is used to treat chronic hepatitis b and HIV in the USA. It has been approved in Europe to treat chronic hepatitis b and HIV infections.
Download report
Favorite
BMS
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
digestive system diseasesD004066
urogenital diseasesD000091642
immune system diseasesD007154
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Viread (generic drugs available since 2015-03-18)
Combinations
Atripla, Cimduo, Complera, Delstrigo, Stribild, Symfi, Symfi lo, Truvada (generic drugs available since 2015-03-18, discontinued: Temixys)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cobicistat
+
Elvitegravir
+
Emtricitabine
+
Tenofovir disoproxil fumarate
Tradename
Company
Number
Date
Products
STRIBILDGilead SciencesN-203100 RX2012-08-27
1 products, RLD, RS
Doravirine
+
Lamivudine
+
Tenofovir disoproxil fumarate
Tradename
Company
Number
Date
Products
DELSTRIGOMerck Sharp & DohmeN-210807 RX2018-08-30
1 products, RLD, RS
Efavirenz
+
Emtricitabine
+
Tenofovir disoproxil fumarate
Tradename
Company
Number
Date
Products
ATRIPLAGilead SciencesN-021937 RX2006-07-12
1 products, RLD, RS
Efavirenz
+
Lamivudine
+
Tenofovir disoproxil fumarate
Tradename
Company
Number
Date
Products
SYMFI LOMylanN-208255 RX2018-02-05
1 products, RLD, RS
SYMFIMylanN-022142 RX2018-03-22
1 products, RLD, RS
Show 2 discontinued
Emtricitabine
+
Rilpivirine hydrochloride
+
Tenofovir disoproxil fumarate
Tradename
Company
Number
Date
Products
COMPLERAGilead SciencesN-202123 RX2011-08-10
1 products, RLD, RS
Emtricitabine
+
Tenofovir disoproxil fumarate
Tradename
Company
Number
Date
Products
TRUVADAGilead SciencesN-021752 RX2004-08-02
4 products, RLD, RS
Lamivudine
+
Tenofovir disoproxil fumarate
Tradename
Company
Number
Date
Products
CIMDUOMylanN-022141 RX2018-02-28
1 products, RLD, RS
Show 2 discontinued
Tenofovir disoproxil fumarate
Tradename
Company
Number
Date
Products
VIREADGilead SciencesN-021356 RX2001-10-26
4 products, RLD, RS
VIREADGilead SciencesN-022577 RX2012-01-18
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
atriplaNew Drug Application2021-12-14
cimduoNew Drug Application2021-02-15
complera accessExport only2021-03-29
delstrigoNew Drug Application2021-10-31
efavirenz, emtricitabine and tenofovir disoproxil fumarateANDA2023-01-27
emtricitabine and tenofovir disoproxil fumarateANDA2023-06-15
stribildNew Drug Application2021-09-16
symfiNew Drug Application2019-10-15
temixysNew Drug Application2021-01-25
truvadaNew Drug Application2022-01-20
Show 1 more
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
chronic hepatitis bEFO_0004239D019694B18.1
hiv—D006678O98.7
Agency Specific
FDA
EMA
Expiration
Code
DORAVIRINE / LAMIVUDINE / TENOFOVIR DISOPROXIL FUMARATE, DELSTRIGO, MSD MERCK CO
2025-01-27NPP
2023-08-30NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate, Delstrigo, Msd Merck Co
106032822036-11-29DP
108427512036-11-29DP
84869752031-10-07DS, DPU-2395, U-2629, U-3307
Emtricitabine / Rilpivirine Hydrochloride / Tenofovir Disoproxil Fumarate, Complera, Gilead Sciences Inc
108571022033-01-14DP
88413102025-12-09DPU-257
71258792025-04-21DS, DPU-257
80805512023-04-11DS, DP
Cobicistat / Elvitegravir / Emtricitabine / Tenofovir Disoproxil Fumarate, Stribild, Gilead Sciences Inc
100397182032-10-06DP
86332192030-04-30DPU-257
81483742029-09-03DS, DPU-1279
98912392029-09-03DPU-257
76357042026-10-26DS, DPU-257
89811032026-10-26DS, DP
71762202026-08-27DS, DPU-257
85923972024-01-13DPU-248, U-257, U-541, U-750, U-1170
87162642024-01-13DPU-257
94570362024-01-13DPU-257
97441812024-01-13DPU-257
Efavirenz / Emtricitabine / Tenofovir Disoproxil Fumarate, Atripla, Gilead Sciences
85981852029-04-28DP
90181922026-06-13U-750, U-1170
95454142026-06-13DPU-750, U-1170
ATC Codes
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AF: Nucleoside and nucleotide reverse transcriptase inhibitors
— J05AF07: Tenofovir disoproxil
— J05AR: Antivirals for treatment of hiv infections, combinations
— J05AR03: Tenofovir disoproxil and emtricitabine
— J05AR06: Emtricitabine, tenofovir disoproxil and efavirenz
— J05AR08: Emtricitabine, tenofovir disoproxil and rilpivirine
— J05AR09: Emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat
— J05AR11: Lamivudine, tenofovir disoproxil and efavirenz
— J05AR12: Lamivudine and tenofovir disoproxil
— J05AR24: Lamivudine, tenofovir disoproxil and doravirine
— J05AR27: Lamivudine, tenofovir disoproxil and dolutegravir
HCPCS
No data
Clinical
Clinical Trials
736 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B202971767748288
Chronic hepatitis bD019694EFO_0004197B18.11325173828117
HivD006678O98.71911144622110
Hepatitis bD0065095158161355
Healthy volunteers/patients—21——6229
Acquired immunodeficiency syndromeD000163EFO_0000765B202262214
InfectionsD007239EFO_0000544—363—12
Medication adherenceD055118EFO_00063443123110
Hiv-1D015497—234—9
PregnancyD011247EFO_0002950Z33.11322—8
Show 37 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Covid-19D000086382U07.1—35—16
Sars-cov-2D000086402—12——2
Chronic hepatitis dD019701—11——2
LymphomaD008223C85.9111——2
Treatment adherence and complianceD000074822——2——2
Breast feedingD001942——1——1
Coronavirus infectionsD018352EFO_0007224B34.2——1——1
B-cell lymphomaD016393——1——1
Disease progressionD018450——1——1
Hiv seronegativityD018023—11——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hepatitis dD003699EFO_0007304—4———4
Biliary liver cirrhosisD008105K74.3—1——12
Metabolic syndromeD024821EFO_0000195E88.81—1——12
LipodystrophyD008060E88.1—2———2
ParasitemiaD01851211———1
Progressive multifocal leukoencephalopathyD007968EFO_0007455A81.2—1———1
Hiv seropositivityD006679—1———1
Amphetamine-related disordersD019969EFO_0004701F15—1———1
B-cell chronic lymphocytic leukemiaD015451C91.1—1———1
Large b-cell lymphoma diffuseD016403C83.3—1———1
Show 5 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Drug interactionsD0043471———12
ContraceptionD0032671———12
Gender dysphoriaD000068116F641————1
TransgenesD0190761————1
Insulin resistanceD007333EFO_00026141————1
Amyotrophic lateral sclerosisD000690EFO_0000253G12.211————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pregnancy rateD018873————22
Risk reduction behaviorD040242————22
Sustained virologic responseD000072230————11
Job syndromeD007589EFO_0003775D82.4————11
InflammationD007249————11
InfertilityD007246EFO_0000545————11
Liver failureD017093HP_0001399K72.9————11
Virus diseasesD014777B34————11
ProteinuriaD011507HP_0000093R80————11
HyperglycemiaD006943HP_0003074R73.9————11
Show 10 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTENOFOVIR DISOPROXIL
INNtenofovir
Description
Tenofovir (anhydrous) is a member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens is replaced by a [(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(isopropyloxycarbonyloxymethyl) ester (disoproxil ester) prodrug is used as the fumaric acid salt in combination therapy for the treatment of HIV infection. It has a role as a HIV-1 reverse transcriptase inhibitor, an antiviral drug and a drug metabolite. It is a member of phosphonic acids and a nucleoside analogue. It is a conjugate acid of a tenofovir(1-).
Classification
Small molecule
Drug classantivirals
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)OCOC(=O)OC(C)C
Identifiers
PDB—
CAS-ID147127-20-6
RxCUI117466
ChEMBL IDCHEMBL1538
ChEBI ID63717
PubChem CID464205
DrugBankDB00300
UNII IDW4HFE001U5 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Complera - Gilead Sciences
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Truvada - Gilead Sciences
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Atripla - Gilead Sciences
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Viread - Gilead Sciences
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Stribild - Gilead Sciences
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 27,160 documents
View more details
Safety
Black-box Warning
Black-box warning for: Atripla, Cimduo, Complera access, Delstrigo, Efavirenz, emtricitabine and tenofovir disoproxil fumarate, Emtricitabine and tenofovir disoproxil fumarate, Stribild, Symfi, Temixys, Truvada, Viread
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
11,241 adverse events reported
View more details